Physician profile
Mark E Kaplan
NPI 1861591661
$9,776.77
in general payments reported to CMS, 2019-2025
30 companies · $88.84 in 2025
The $88.84 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,568 · 2020: $1,075 · 2021: $1,498 · 2022: $1,547 · 2023: $1,926 · 2024: $2,074 · 2025: $88.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,067 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,066.82 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,946.35 | 2019-2024 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,449.41 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,410.20 | 2019-2024 | |
| Optinose US, INC. | $780.30 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $726.73 | 2021-2024 | Dupixent |
| Genentech USA, INC. | $455.78 | 2019-2024 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.40 | 2019-2024 | Spiriva Respimat |
| Kaleo, INC. | $325.99 | 2019-2024 | Auvi-Q |
| Csl Behring | $274.64 | 2020-2023 | Haegarda, Kcentra |
| Pfizer INC. | $271.83 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $236.73 | 2020-2024 | Takhzyro |
| Teva Pharmaceuticals USA, INC. | $210.16 | 2019-2021 | |
| Alk-Abello, INC | $206.59 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $174.96 | 2020-2024 | |
| Biocryst US Sales Co., LLC | $135.30 | 2022-2024 | Orladeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $112.06 | 2022-2024 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $88.84 | 2025 | Neffy |
| Octapharma USA, INC. | $80.66 | 2021 | |
| Adma Biomanufacturing LLC | $68.33 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $60.38 | 2022 | |
| Blueprint Medicines Corporation | $53.21 | 2024 | Ayvakit |
| Shire North American Group INC | $46.68 | 2019 | |
| Covis Pharma Gmbh | $46.45 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $44.89 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $39.85 | 2024 | Ryaltris |
| Merck Sharp & Dohme LLC | $37.83 | 2021-2023 | |
| Leo Pharma INC. | $23.02 | 2022 | |
| Grifols USA, LLC | $19.63 | 2020 | |
| Phadia US INC. | $14.94 | 2022 | |
| Eyevance Pharmaceuticals LLC | $13.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.